Acquisition adds 30 products to Biolab’s portfolio
Biolab Pharma, on July 2, assumed the operations of Actavis Brasil, acquired from Teva laboratory, which includes an industrial facility in Rio de Janeiro and a 30-product portfolio comprised of brands and generic drugs. Due to the non-disclosure agreement between the parties, the transaction price will not be disclosed.
In line with the strategic guideline of strengthening its market share in high potential therapeutic areas, this deal allows Biolab to consolidate itself in the Central Nervous System (CNS) disease segment, one of the most promising in the pharmaceutical industry. In addition, the acquisition makes the creation of a new business platform based on generic products feasible, complementing its extensive line of exclusive products, reputed brands and over-the-counter drugs.
“Actavis Brasil was an excellent acquisition for Biolab, fully in line with our strategic plan. We merged reputed brands, as well as differentiated generic drugs, which positions us in new relevant pharmaceutical industry segments. Additionally, it strengthens our market share in the institutional sales channels, focused on hospitals and governments, and we approach neurologists and psychiatrists, two important areas of medicine”, explained Cleiton Castro Marques, Biolab’s CEO. At least 12 releases are scheduled to happen by 2019.
Biolab consolidates its market share in Central Nervous System, reinforces its operation in the institutional channel and complements its offer with a generic product platform.
“Innovation and focus on research and development represent Biolab’s spirit. We work to be more and more recognized by the market as an innovative industry. For such purpose, we invest about 10% of our revenue in R&Dannually, we launched a Research Center in Canada and we have dozens of ongoing innovative projects. We are already leaders in cardiology and have a strong activity in women’s health, dermatology and other areas. Actavis’ acquisition enables us to relevantly act in one more important segment: Central Nervous System. It also allows for Biolab to complement its offer by means of a generic drug unit, in order to expand the population’s access to innovative and high quality drugs”, complemented Cleiton de Castro Marques.
Actavis incorporates 100 new employees into Biolab, which now has over 2,800 professionals. Biolab will also expand its sales team, one of the biggest in the Brazilian pharmaceutical industry, to work with the new products in its portfolio.
Brazilian pharmaceutical industry with international market share, Biolab consolidates its path based on the commitment of offering health and life quality to the population. With more than 2,800 employees, it is one of the top 5 biggest pharmaceutical companies in Brazil, a reference in global market, with solid commitment to the science development. Leader in the Brazilian prescription drug market in the Cardiology area, the company also has a relevant activity in Women’s Health, Dermatology, Pediatrics, Central Nervous System, Angiology, Orthopedics & Rheumatology, and Dermocosmetics, amongst others. The company has one of the most modern Centers of Research, Development and Innovation (RD&I) in Brazil, in addition to a Center of RD&I in Mississauga (Canada). The growing performance is a result of partnerships with universities, laboratories and research centers. In addition, it maintains a solid social responsibility policy. More information at: www.biolabfarma.com.br/en.
Source: Texto Comunicação Corporativa